References

References:

1. Reuterina® Drops Approved Package Insert, August 2009.
2. Reuterina® Vit D (drops) Approved Package Insert, August 2013.
3. Reuterina® Junior Approved Package Insert, July 2010.
4. Reuterina® Daily Approved Package Insert, July 2010.
5. Reuterina® Acute Approved Package Insert, March 2010.
6. Reuterina® Femme® Approved Package Insert, December 2009.
7. Reuterina® Lozenges Approved Package Insert, October 2017.
8. Savino F, et al. Lactobacillus reuteri DSM 17 938 in infantile colic: A randomized, double-blind, placebo- controlled trial. Pediatrics 2010;126:e526-e533.
9. MiGL, Zhao L, Qiao DD, et al. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 2015;107(154):1557-1553.
10. Chau K, et al. Probiotics for infantile colic: a randomized double-blind placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2014;166:74-78.
11. Szajewska H, et al. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A randomized, double-blind, placebo-controlled trial. J Pediatr 2013;162:257-262.
12. Indrio F, et al. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 2008;152:801-806.
13. Indrio F et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011;41:417-422.
14. Indrio F, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation. A randomized clinical trial. JAMA Pediatr 2014;168:228-233.
15. Coccorullo P, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatrics 2010;157: 598-602.
16. Olgac MAB, et al. Comparison of probiotic and lactulose treatments in children with functional constipation and determination of the effects of constipation treatment on quality of life. Cocuk Sağlığı ve Hastalıkları Dergisi [Turkish Pediatric Journal] 2013;56:1-7.
17. Weizman Z, et al. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr 2016;174:160-164.
18. Romano C, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50(10):E68-E71.
19. Jadresin O, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children – RCT study. J Pediatr Gastroenterol Nutr 2017;64:925-929.
20. Johnston BC et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD004827. DOI: 10.1002/14651858.CD004827.pub2.
21. Lionetti E, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2006;24:1461-1468.
22. Dinleyici EC, Vandenplas Y, et al, PROBAGE Study Group. Lactobacillus reuteri DSM17938 effectively reduces the duration of acute diarrhea in hospitalised children. Acta Paediatr. 2014;103:e300-e305.
23. Dinleyici EC, et al. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J) 2015;91:392-396.
24. Eom T-H, et al. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J Ped 2005;48:986-989.
25. Shornikova AV, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399-404.
26. Agustina R, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics 2012;129:e1155-e1164.
27. Gutierrez-Castrellon P, et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 2014;133(4):e904-e909.
28. Weizman Z, et al. Effect of a probiotic infant formula on infections in child-care centers: Comparison of two probiotic agents. Pediatrics 2005;115:5-9.
29. Ojetti V, laniro G, Tortora A, et al. Effect of Lactobacillus reuteri. supplementation in adults with chronic functional constipation: a randomised double-blind. placebo-controlled trial. J Gastrointestin Liver Dis 2014;23:387-391.
30. Riezzo G, Orlando A, D’Attoma B, et al. Randomised double blind placebo-controlled trial on Lactobacillus reuteri DSM 17938 improvement in symptoms and bowel habit In functional constipation. Benef Microbes 2016;9:51-60.
31. OjettiV, Petruzziello C, Migneco A, et al. Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation a retrospective study. Eur Rev Med Pharmacol Sci 2017;21:1702-1708.
32. Dumitru IM, Kugina S, Cosma L, et al. The effect of Lactobacillus reuteri therapy in intestinal disorders of various causes in HIV-infected patients infectious. 2009;20(4):18-21. (Published in a Romanian Journal for physicians specialized in infectious diseases. and translated to English.)
33. Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: A randomised, double-blind placebo-controlled study. Environmental Health: A Global Access Science Source 2005;4:25. doi:10.1186/1476-069X-4-25.
34. SchröderC, Schmidt S, Garbe E, et al. Effects of the regular intake of the probiotic Lactobacillus reuteri (DSM 17938) on respiratory and gastrointestinal infections in a workplace setting: a double-blind randomized placebo- controlled trial. BMC Nutrition 2015;1:3.
35. Cimperman L, Bayless G, Best K, et al. A randomized. Double-blind. Placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhoea in hospitalized adults. J Clin Gastroenterol 2011;45:785-789.
36. OjettiV, Bruno G, Ainora ME, et al. Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second line therapy. Gastroenterol Res Pract 2012:7403-7481.
37. Di NardoG, Oliva S, Menichella A, et al. Randomised clinical trial: Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr 2014;58:81-86.
38. Mayo Clinic definition: http://www.mayocinic.org/diseases-conditions/yeast-infection/basics/definition/con-20035129 accessed October 2017
39. Martinez RCR, Franceschini SA et al. Improved treatment of vulvovaginal candidiasis with fluconaze plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
40. Petricevic L, Unger FM et al. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. European Journal of Obstetrics and Gynecology and Reproductive Biology 141(2008) 54-57. 
41. Miraglia del Giudice M. Maiello N. Decimo F, et al. Airways allergic inflammation and Lactobacillus reuteri treatments in asthmatic children. Journal of Biological Regulators & Homeostatic Agents2012; 26(1S):35-30.
42. Ciprandi G. Varrichio A. Vitamin D3 plus Lactobacillus reuteri DSM 17938 as adjuvant for allergen immunotherapy: a preliminary experience. JJ Aller Immuno 2015;2(2):014

Ref: 075 ZA Reut 0919